BIOKANGTAI Overview
- Founded
-
1992
- Status
-
Public
- Employees
-
2,445
- Stock Symbol
-
300601
- Share Price
-
$5.52
- (As of Friday Closing)
BIOKANGTAI General Information
Description
Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
SHE
Primary Office
- No.18,Shutianpu Road
- Guangming District
- Shenzhen, Guangdong 518107
- China
+86 0755 0000 0000
BIOKANGTAI Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.52 | $5.62 | $3.76 - $9.40 | $6.19B | 1.12B | 12.9M | -$0.02 |
BIOKANGTAI Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 4,727,212 | 10,350,430 | 18,113,118 | 8,111,072 |
| Revenue | 585,821 | 565,595 | 327,298 | 281,249 |
| EBITDA | 66,297 | 276,217 | 122,111 | 108,810 |
| Net Income | 65,649 | 195,658 | 98,310 | 83,146 |
| Total Assets | 1,945,059 | 2,219,762 | 1,467,024 | 564,888 |
| Total Debt | 322,840 | 429,567 | 13,957 | 36,591 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BIOKANGTAI Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BIOKANGTAI Patents
BIOKANGTAI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021105902-A4 | Tetravalent influenza virus chicken embryo culture processes, tetravalent influenza virus split vaccines and preparation methods thereof | Active | 19-Aug-2021 | 00000000 | |
| AU-2021107276-A4 | Purification process of chicken embryo allantoic fluid of tetravalent influenza virus, tetravalent influenza virus split vaccine and preparation method thereof | Active | 29-Dec-2020 | 000000000 |
BIOKANGTAI Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Weimin Du | Chairman & Board Member | ||
| Haifa Zheng | Board Member & Vice Chairman |
BIOKANGTAI Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Haifa Zheng | BIOKANGTAI | Board Member & Vice Chairman | 000 0000 |
| Weimin Du | BIOKANGTAI | Chairman & Board Member | 000 0000 |
BIOKANGTAI Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BIOKANGTAI Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BIOKANGTAI ESG
Risk Overview
Risk Rating
Updated May, 06, 2022
30.55 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
00.0
Percentile
Pharmaceuticals
Industry
00 of 1,004
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 462
Rank
00.00
Percentile
